Resources

The interim results, after 8 weeks of treatment, showed no change in fasting glucose while in post-prandial glucose there was a 15.4% reduction.

New data, suggest that the novel long-acting insulin, insulin detemir (Novo Nordisk) can be used in people with type 2 diabetes without causing weight gain of the degree that typically accompanies this progression of therapy.

Supplementation of a meal based on white wheat bread with vinegar reduced postprandial responses of blood glucose and insulin, and increased the subjective rating of satiety.

References for Item 11

A regulatory review and approval last Thursday of a potential blockbuster drug for diabetes is being viewed on Wall Street as a ”test case” that may reveal whether the Food and Drug Administration has become more cautious about safety.

Researchers report that the addition of a drug, spironolactone, to standard blood pressure-lowering therapy helps reduce both blood pressure and the amount of albumin protein in urine by 33%, a measure of kidney impairment.

The FDA has approved the investigational oral medicine for the treatment of type 2 diabetes, for use as monotherapy and in combination with metformin.

A government advisory panel backed approval of an insulin inhaler Thursday, for the first time potentially offering adult diabetics an alternative to injections for controlling their blood sugar.

Acute insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in patients with long-standing type 1 diabetes. The phenomenon represents “an important counter-regulatory mechanism to hypoglycemia.

Results of the study showed that most strokes and heart attacks can be abolished or reduced by 50% by simply combining modern blood pressure lowering drugs as amlodipine and perindopril, plus effective lowering of cholesterol, which also reduced new cases of diabetes by 30%.